Freezing UK Statutory Scheme Rebate Could Cost UK Government Over £15m
Executive Summary
Accepting the pharmaceutical industry’s request to keep the statutory scheme rebate rate at its current rate this year could cost the government dearly, but raising it as planned could be detrimental for UK life sciences.
You may also be interested in...
Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’
The pharmaceutical industry and the UK government are beginning a series of discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.
More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences
In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.
Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme
As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.